The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study
Abstract Background Percutaneous coronary intervention (PCI) is one of the most performed well-succeeded therapeutic procedures worldwide, reducing symptoms and improving quality of life. Neutrophil Gelatinase-associated Lipocalin (NGAL) is a biomarker of acute kidney injury (AKI) produced early aft...
Main Authors: | Mateus Paiva Marques Feitosa, Eduardo Gomes Lima, Alexandre Antônio Cunha Abizaid, Roxana Mehran, Neuza Helena Moreira Lopes, Thiago de Assis Fischer Ramos, Alexandre Hideo-Kajita, Roberto Kalil Filho, Carlos Vicente Serrano Junior |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-06-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13098-023-01107-9 |
Similar Items
-
The Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarction
by: Uğur Özkan, et al.
Published: (2023-03-01) -
Effect of SGLT2 inhibitor on patients with STEMI complicated with type 2 diabetes mellitus after PCI
by: Du Shengli, Jia Zengqin, Zhang Qihua
Published: (2023-04-01) -
Rate of Urgent Coronary Artery Bypass Grafting in Elective Percutaneous Coronary Intervention (PCI)
by: Seyed Amir Kassaei, et al.
Published: (2008-01-01) -
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
by: Damilola D. Adingupu, et al.
Published: (2019-02-01) -
Different hydration methods for the prevention of contrast-induced nephropathy in patients with elective percutaneous coronary intervention: a retrospective study
by: Fei Chen, et al.
Published: (2023-06-01)